Israel’s Everads Therapy, a biotech startup developing optimized retinal therapies by leveraging its novel suprachoroidal delivery technology, and VivaVision, a pharmaceutical company developing innovative therapies for ocular diseases, are partnering to develop safer, more effective, and more durable treatments for retinal diseases.
The two companies will develop certain undisclosed molecules of VivaVision for suprachoroidal delivery using Everads’ technology and expertise. The molecules selected are potent small molecules that work against well-validated therapeutic targets in retinal disease management, and that are designed to enable extended durability in the suprachoroidal space.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
Founded in 2017, Everads Therapy is a small early-stage life sciences company developing the next generation of retinal treatment delivery technologies. The company says that its goal is to overcome significant challenges in current treatment methodologies for retinal and macular diseases, Everads’ delivery system offers the promise of improving the efficacy and safety of existing and potential drug therapies. Everads Therapy operates within the RAD Biomed incubator in Tel Aviv, Israel. Its underlying technologies have been licensed from the Sheba Medical Center at Tel Hashomer.
“We are excited about the potential of delivering our treatments for posterior eye diseases through the suprachoroidal space using Everads’ technology, an approach that we believe will demonstrate strong efficacy and durability, potentially bringing life-changing improvements to populations throughout the world,” commented Wang Shen, PhD, CEO of VivaVision.
Moshe Weinstein, Executive Chairman and acting CEO of Everads, added, “We believe that VivaVision’s drug candidates and formulations offer significant potential for the treatment of retinal disease via suprachoroidal administration with our technology. We look forward to working together to increase treatment safety, effectivity and durability.”
Under the terms of collaboration agreement, the companies will jointly conduct pre-clinical research activities, in order to identify lead candidates for future clinical development and commercialization. Everads and VivaVision will share costs of the research plan, and have rights in a future joint venture which will hold the commercialization rights of the research results. YAFO Capital (Shanghai) acted as VivaVision’s advisor on this transaction.
VivaVision is a clinical stage pharmaceutical company focused on “best-in-class and first-in-class” therapies for ocular diseases. Besides VVN001 program, VivaVision is developing VVN539 for the treatment for Glaucoma or Ocular Hypertension, and VVN461 for the treatment of non-infectious anterior uveitis and post-operative inflammation. VivaVision is also engaged in discovery and development of novel therapies for the treatment of other anterior and posterior eye diseases. VivaVision is led by experienced drug hunters in the fields of ophthalmology. The company is inspired to be a global leader of ophthalmic drug discovery. VivaVision is backed by leading life sciences investors including Sequoia, Lapam, Cenova, GTJA, etc.
